Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty
Open Access
- 6 May 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e62709
Abstract
Total knee arthroplasty (TKA) is common, effective, and cost-effective. Innovative implants promising reduced long-term failure at increased cost are under continual development. We sought to define the implant cost and performance thresholds under which innovative TKA implants are cost-effective. We performed a cost-effectiveness analysis using a validated, published computer simulation model of knee osteoarthritis. Model inputs were derived using published literature, Medicare claims, and National Health and Nutrition Examination Survey data. We compared projected TKA implant survival, quality-adjusted life expectancy (QALE), lifetime costs, and cost-effectiveness (incremental cost-effectiveness ratios or ICERs) of standard versus innovative TKA implants. We assumed innovative implants offered 5–70% decreased long-term TKA failure rates at costs 20–400% increased above standard implants. We examined the impact of patient age, comorbidity, and potential increases in short-term failure on innovative implant cost-effectiveness. Implants offering ≥50% decrease in long-term TKA failure at ≤50% increased cost offered ICERs <$100,000 regardless of age or baseline comorbidity. An implant offering a 20% decrease in long-term failure at 50% increased cost provided ICERs <$150,000 per QALY gained only among healthy 50–59-year-olds. Increasing short-term failure, consistent with recent device failures, reduced cost-effectiveness across all groups. Increasing the baseline likelihood of long-term TKA failure among younger, healthier and more active individuals further enhanced innovative implant cost-effectiveness among younger patients. Innovative implants must decrease actual TKA failure, not just radiographic wear, by 50–55% or more over standard implants to be broadly cost-effective. Comorbidity and remaining life span significantly affect innovative implant cost-effectiveness and should be considered in the development, approval and implementation of novel technologies, particularly in orthopedics. Model-based evaluations such as this offer valuable, unique insights for evaluating technological innovation in medical devices.Keywords
This publication has 51 references indexed in Scilit:
- Medical Device Innovation — Is “Better” Good Enough?New England Journal of Medicine, 2011
- Forecasting the burden of advanced knee osteoarthritis over a 10-year period in a cohort of 60–64 year-old US adultsOsteoarthritis and Cartilage, 2011
- Future Young Patient Demand for Primary and Revision Joint Replacement: National Projections from 2010 to 2030Clinical Orthopaedics and Related Research, 2009
- Determinants of self‐reported health status in a population‐based sample of persons with radiographic knee osteoarthritisArthritis Care & Research, 2009
- Survival and clinical function of cemented and uncemented prostheses in total knee replacementThe Journal of Bone and Joint Surgery. British volume, 2009
- Cost-effectiveness of Total Knee Arthroplasty in the United StatesArchives of internal medicine (1960), 2009
- Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets studyThe European Journal of Health Economics, 2008
- Tamoxifen for Breast Cancer Risk ReductionMedical Care, 2008
- Implant Selection and Cost for Total Joint ArthroplastyClinical Orthopaedics and Related Research, 2007
- The Influence of Income and Race on Total Knee Arthroplasty in the United StatesJournal of Bone and Joint Surgery, 2006